CN1160560A - Chinese patent drug for curing leukopenia and its preparation process - Google Patents
Chinese patent drug for curing leukopenia and its preparation process Download PDFInfo
- Publication number
- CN1160560A CN1160560A CN 96118646 CN96118646A CN1160560A CN 1160560 A CN1160560 A CN 1160560A CN 96118646 CN96118646 CN 96118646 CN 96118646 A CN96118646 A CN 96118646A CN 1160560 A CN1160560 A CN 1160560A
- Authority
- CN
- China
- Prior art keywords
- radix
- rhizoma
- parched
- fructus
- atractylodis macrocephalae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The said Chinese patent drug consists of 24 kinds of Chinese medicinal material including Epimedium, Psoralea corylifalia, Herba hedyotis diffusae, bushy knotweed, etc. and it may be prepared in capsule or granule. Compared with available technology, the present invention has determined curative effect, fast leucocyte increasing speed, comprehensive organism regulating and improving capability, low cost and no toxic side effect, so that the new drug is easy to accept by patient..
Description
The invention belongs to Chinese patent drug technique field, relate to a kind of shengbai drug and processing technology thereof that cures mainly leukopenia.
For a long time, leukopenia is a thorny difficult problem.Leukopenia is meant that the peripheral blood leucocyte counting continues to be lower than 4000/mm
3, wherein mainly be granulocytopenia, when the granulocyte absolute number is lower than 1500/mm
3The time, be called granulocytopenia, even be called agranulocytosis when lacking fully, the low mostly 1000/mm of its numeration of leukocyte
3The morbidity of leukopenia is main to be generated with granulocyte and reduces, destroys or to consume too much, granulocyte distribution disorder etc. relevant.The case fatality rate of Schwartz's syndrome is in the past up to 70-90%.At present, the granulocytopoietic medicine a multitude of names of so-called promotion, as the clinical batilol of commonly using, leucogen, DNA (deoxyribonucleic acid), flesh liver, coenzyme A, lithium carbonate, 654-2, vitamin B, etc. Western medicine, curative effect is all dissatisfied.In recent years by the biological preparation GM-CSF of external import, this disease there is curative effect preferably, but certain side effect is arranged, its price 7 costlinesses particularly, need about 5000 yuans of cost a course of treatment (5 days), the patient generally is difficult for accepting, and its applying at home is restricted.By the disclosed CN93101219.8 of Chinese patent communique, what No. 93105154.1 patent applications of CN proposed improves the shengbai drug of human leukocytes, thrombocytopenia with Chinese medicine, a kind of effective force method of can yet be regarded as, but its composition principle only is QI invigorating or enriches blood, whether reasonable, need the proof of practice, and fill a prescription and form simply, do not have special medication, in clinical practice, do not see good especially curative effect report as yet.
At above-mentioned prior art situation, higher in view of this sick sickness rate again, harm bigger, the object of the present invention is to provide a kind of preparation and processing technology thereof of pure Chinese medicinal ingredients newly, make its have curative effect really, rise white fast, human body is had comprehensive adjustment and improvement effect, and non-pigment, no glucide, preservative free, have no side effect, cheap, easily accepted by extensive patients.
Now design of the present invention and technical solution are described below:
According to the traditional medical theory of motherland, think that the pathogenic factor of primary disease mainly is an asthenia of essence and blood, due to the deficiency of both QI and YIN.Chinese medicine is thought: " the kidney being the origin of congenital constitution ", " the spleen being the foundation of acquired constitution ", " essence and blood sharing the same origin ", " qi being the governor of blood ", " blood being the material foundation of QI ", so it is main that the present invention has drafted strengthening spleen, tonifying kidney, the benefiting QI and nourishing blood spermatogenesis is the Therapeutic Principle who assists, and has formed the basic side and the full side of powerful shengbai drug.Herba Hedyotidis Diffusae, the Rhizoma Polygoni Cuspidati of special efficacy are arranged in vain is principal agent with the Herba Epimedii of the kidney invigorating and essence nourishing, Fructus Psoraleae, Semen Cuscutae, Placenta Hominis, Radix Polygoni Multiflori Preparata with to rising in the side; Radix Panacis Quinquefolii (or Radix Ginseng), the Radix Astragali, Radix Angelicae Sinensis, the Rhizoma Atractylodis Macrocephalae, Caulis Spatholobi, Colla Corii Asini, the Radix Paeoniae Alba, Rhizoma Polygonati (processed), Radix Rehmanniae Preparata with the invigorating the spleen and benefiting QI hemopoietic are accessory drugs; To give birth to Fructus Ligustri Lucidi, Herba Ecliptae, Radix Ophiopogonis, Fructus Lycii is adjuvant drug; With Semen Ziziphi Spinosae, Fructus Crataegi (parched to brown), Radix Glycyrrhizae, Rhizoma Chuanxiong is messenger drug.All medicines share, qi and blood tonifying, and giving consideration to both the incidental and fundamental stimulates granulocytic generation, adjusts body QI and blood, equilibrium between yin and yang and reaches the purpose of treatment.
Basic side of the present invention is (by weight percentage) with the composition and the proportioning of full side:
Substantially square:
Radix Polygoni Multiflori Preparata 4-12 Herba Epimedii 2.5-3.5 Rhizoma Polygonati (processed) 4-12
Rhizoma Atractylodis Macrocephalae (parched with earth) 3-9 Radix Panacis Quinquefolii (or Radix Ginseng) 2.5-7.5
Radix Angelicae Sinensis 2.5-7.5 Colla Corii Asini 2.5-7.5 Fructus Crataegi (parched to brown) 1.5-4.5
Herba Hedyotidis Diffusae 1.5-4.5 Radix Glycyrrhizae 0.5-1.5
Full side:
Radix Astragali 3-9 Radix Angelicae Sinensis 3-9 Caulis Spatholobi 2.5-7.5
Radix Rehmanniae Preparata 2.5-7.5 Rhizoma Polygonati (processed) 2.5-7.5 Rhizoma Atractylodis Macrocephalae (parched with earth) 2.5-7.5
Radix Paeoniae Alba 2.5-7.5 gives birth to Fructus Ligustri Lucidi 2.5-7.5 Herba Ecliptae 2.5-7.5
Radix Ophiopogonis 2.5-7.5 Semen Cuscutae 2.5-7.5 Colla Corii Asini 2.5-7.5
Radix Panacis Quinquefolii (or Radix Ginseng) 2-6 Fructus Lycii 2.5-7.5
Semen Ziziphi Spinosae 1.5-4.5 Fructus Crataegi (parched to brown) 1.5-4.5 Placenta Hominis 0.25-0.7 5
Radix Polygoni Multiflori Preparata 2.5-7.5 Radix Glycyrrhizae 0.5-1.5 Herba Epimedii 2-6
Herba Hedyotidis Diffusae 1.5-4.5 Fructus Psoraleae 1.5-4.5
Rhizoma Polygoni Cuspidati 0.5-1.5 Rhizoma Chuanxiong 0.5-1.5 shengbai drug of the present invention can be made into capsule formulation, also can be made into the electuary dosage form, and it is medicinal identical, is for being suitable for all ages and classes and different state of an illness patient's taking conveniences.Now processing technology is described below respectively:
1, paste capsule of rising white blood cell
In the ratio of basic side or full side, take by weighing each medicine (containing) from Fructus Crataegi and the Rhizoma Atractylodis Macrocephalae (parched with earth) concocted, in oven dry below 80 ℃, mixing is pulverized, and crosses 100 mesh sieves, is sub-packed in No. 1 capsule, and every capsule contains crude drug 0.4 gram, stores in the plastic bottle standbyly, with bottled case, uses
60The Co irradiation sterilization is patent medicine.Wherein homemade Fructus Crataegi concocting method is: Fructus Crataegi is fried to outer black, in to be dark brown standby.Homemade Rhizoma Atractylodis Macrocephalae (parched with earth) method is: with the sandy soil oven dry, cross 80 mesh sieves and the Rhizoma Atractylodis Macrocephalae and fry altogether to the little Huang in medical material surface, remove sandy soil after sieve, it is standby to keep the Rhizoma Atractylodis Macrocephalae.
2, rise white electuary:
Ratio in basic side or full side takes by weighing each medicine, decocts with water twice, for the first time add 10 times of amounts of water (by weight), decocted 2-4 hour, add 8 times of amounts of water for the second time, decocted 1.5-2.5 hour, collecting decoction filters, supernatant adds 2 times of 95% ethanol precipitation and spends the night, get its supernatant, behind the decompression recycling ethanol, when waiting to be concentrated into finite concentration, staticly settled 20-30 hour, filter, filtrate with low-temperature evaporation to the thick paste shape, thick paste proportion with 1.30-1.35 be advisable (80 ℃ of-90 ℃ of intermittent fever are surveyed) get 1 part of thick paste, 3 parts of sucrose, 1 part of mixing of dextrin is made granule, and the 12-14 mesh sieve is crossed in dry back, get final product packing, again warp
60Behind the Co irradiation sterilization, be patent medicine.
The present invention shows through 920 routine clinical researches, the average recovery rate of peripheral leukocytes in patients number in two weeks after the treatment of this medicine is 91.8%, to dizziness, weak, extremity are aching and limp, insomnia and dreamful sleep, loss of appetite, low grade fever, fear the improvement rate average out to 94.2% of eight common symptons such as cold grade, particularly poor at improving appetite, dizzy, weak aspect, curative effect is more obvious, the improvement rate is respectively 99.5%, 96.4%, 95.2%. take this medicine continuously, clinical symptoms disappearance rate in month reaches more than 95%, and can strengthen the patient immune function, improve muscle power and endurance, improve patient's total quality.The present invention also takes this clinical drug to 428 routine tumour patients and studies show that when accepting radiation and chemotherapy, patient's peripheral white blood cell of 71.3% remained in normal range, patient's peripheral blood leucocyte of 25% has rising in various degree, and the average improvement rate of patient's various clinical symptoms is 93.4%.In addition, show that by 246 routine anemia patients and 121 routine thrombocytopenia patients application effective percentage is respectively 92.4% and 85.9%, demonstrate good efficacy anemia and thrombocytopenia.
" the equal avirulence of each medicine in the Chinese pharmacopoeia, the present invention prescription shows that this medicine is taken for a long time, without any side effects and savings toxic and side effects through anxious poison and the slow poison experiment and over thousands of routine patient's applicable cases of rat through consulting.
The present invention with in of the prior art, the Western medicine ratio, curative effect really, rise white fast, body is had comprehensive adjustment and improvement effect, processing technology is simple, cheap.
It is reported, to so far, these type of specially good effect Chinese Traditional Medicines that have no alternative but to official approval is still produced, the present invention provides a kind of original new drug that uses of very easily popularizing for this technical field, have the wide development application prospect, its social benefit and economic benefit are conspicuous.
Claims (4)
1, a kind of white Chinese Traditional Medicines of liter that cure mainly leukopenia is characterized in that with Herba Epimedii, Fructus Psoraleae, Semen Cuscutae, Placenta Hominis, Radix Rehmanniae Preparata, Radix Polygoni Multiflori Preparata, Herba Hedyotidis Diffusae, Rhizoma Polygoni Cuspidati be principal agent; With Radix Panacis Quinquefolii (or Radix Ginseng), the Radix Astragali, Radix Angelicae Sinensis, the Rhizoma Atractylodis Macrocephalae, Caulis Spatholobi, Colla Corii Asini, the Radix Paeoniae Alba, Rhizoma Polygonati (processed) is accessory drugs; To give birth to Fructus Ligustri Lucidi, Herba Ecliptae, Radix Ophiopogonis, Fructus Lycii is adjuvant drug; With Semen Ziziphi Spinosae, Fructus Crataegi (parched to brown), Radix Glycyrrhizae, Rhizoma Chuanxiong is messenger drug.
2, a kind of shengbai drug that cures mainly leukopenia according to claim 1 is characterized in that:
The proportioning that constitutes the basic side of this medicine is (by weight percentage):
Radix Polygoni Multiflori Preparata 4-12 Herba Epimedii 2.5-3.5 Rhizoma Polygonati (processed) 4-12
Rhizoma Atractylodis Macrocephalae (parched with earth) 3-9 Radix Panacis Quinquefolii (or Radix Ginseng) 2.5-7.5
Radix Angelicae Sinensis 2.5-7.5 Colla Corii Asini 2.5-7.5 Fructus Crataegi (parched to brown) 1.5-4.5
Herba Hedyotidis Diffusae 1.5-4.5 Radix Glycyrrhizae 0.5-1.5
The proportioning that constitutes the full side of this medicine is (by weight percentage):
Radix Astragali 3-9 Radix Angelicae Sinensis 3-9 Caulis Spatholobi 2.5-7.5
Radix Rehmanniae Preparata 2.5-7.5 Rhizoma Polygonati (processed) 2.5-7.5 Rhizoma Atractylodis Macrocephalae (parched with earth) 2.5-7.5
Radix Paeoniae Alba 2.5-7.5 gives birth to Fructus Ligustri Lucidi 2.5-7.5 Herba Ecliptae 2.5-7.5
Radix Ophiopogonis 2.5-7.5 Semen Cuscutae 2.5-7.5 Colla Corii Asini 2.5-7.5
Radix Panacis Quinquefolii (or Radix Ginseng) 2-6 Fructus Lycii 2.5-7.5
Semen Ziziphi Spinosae 1.5-4.5 Fructus Crataegi (parched to brown) 1.5-4.5 Placenta Hominis 0.25-0.75
Radix Polygoni Multiflori Preparata 2.5-7.5 Radix Glycyrrhizae 0.5-1.5 Herba Epimedii 2-6
Herba Hedyotidis Diffusae 1.5-4.5 Fructus Psoraleae 1.5-4.5 Rhizoma Polygoni Cuspidati 0.5-1.5
Rhizoma Chuanxiong 0.5-1.5
3, a kind of processing technology that cures mainly the white Chinese Traditional Medicines of liter of leukopenia according to claim 1 has capsule-type and electuary type, it is characterized in that: (1). and the processing technology of capsule formulation is: in the ratio of basic side or full side, take by weighing each medicine (containing) from Fructus Crataegi and the Rhizoma Atractylodis Macrocephalae (parched with earth) concocted, in oven dry below 80 ℃, mixing is pulverized, cross 100 mesh sieves, be sub-packed in No. 1 capsule, every capsule contains crude drug 0.4 gram, stores in the plastic bottle standby, with bottled case, use
60The Co irradiation sterilization is patent medicine.
(2). the capsular processing technology of electuary type is: in the ratio of basic side or full side, take by weighing each medicine, decoct with water twice, add for the first time 10 times of amounts of water (by weight), decocted 2-4 hour, and added 8 times of amounts of water for the second time, decocted 1.5-2.5 hour, collecting decoction, filter, supernatant adds 2 times of 95% ethanol precipitation and spends the night, and gets its supernatant, behind the decompression recycling ethanol, when waiting to be concentrated into finite concentration, staticly settled 20-30 hour, filter, to the thick paste shape, thick paste proportion is with 1.30-1.35 be advisable (80 ℃-90 ℃ of intermittent fever survey) with low-temperature evaporation for filtrate.Get 1 part of thick paste, 3 parts of sucrose, 1 part of mixing of dextrin is made granule, and the 12-14 mesh sieve is crossed in dry back, gets final product packing.Warp again
60Behind the Co irradiation sterilization, be patent medicine.
4, the processing technology that cures mainly the shengbai drug of leukopenia according to claim 3 is characterized in that: homemade Fructus Crataegi concocting method is: Fructus Crataegi is fried to outer black, in to be dark brown standby; Homemade Rhizoma Atractylodis Macrocephalae (parched with earth) method is: with the sandy soil oven dry, cross 80 mesh sieves and the Rhizoma Atractylodis Macrocephalae and fry altogether to surperficial little Huang, remove sandy soil after sieve, it is standby to keep the Rhizoma Atractylodis Macrocephalae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96118646 CN1160560A (en) | 1996-03-21 | 1996-03-21 | Chinese patent drug for curing leukopenia and its preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96118646 CN1160560A (en) | 1996-03-21 | 1996-03-21 | Chinese patent drug for curing leukopenia and its preparation process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1160560A true CN1160560A (en) | 1997-10-01 |
Family
ID=5125220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 96118646 Pending CN1160560A (en) | 1996-03-21 | 1996-03-21 | Chinese patent drug for curing leukopenia and its preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1160560A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092055C (en) * | 2000-06-09 | 2002-10-09 | 中国人民解放军军事医学科学院放射医学研究所 | Chinese medicine preparation |
| CN101953994A (en) * | 2010-10-11 | 2011-01-26 | 于淑萍 | Chinese medicament for treating luekopenia after concurrent chemoradiotherapy |
| CN102406757A (en) * | 2011-11-28 | 2012-04-11 | 河南科技大学第一附属医院 | Traditional Chinese medicine capsule for treating myelodysplastic syndrome and its manufacturing method |
| CN102727666A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Traditional Chinese medicine for treating hepatic and renal yin deficiency type thrombocytopenia |
| CN103301211A (en) * | 2013-06-14 | 2013-09-18 | 袁军清 | Traditional Chinese medicine for treating leukopenia |
| CN103585471A (en) * | 2013-10-18 | 2014-02-19 | 张兆玺 | Traditional Chinese medicine composition for treating thrombocytopenia |
| CN103877486A (en) * | 2014-04-09 | 2014-06-25 | 刘洁 | Medicine for promoting rise of hemameba number after radiotherapy and chemotherapy and preparation method thereof |
| CN105902970A (en) * | 2016-06-29 | 2016-08-31 | 李翠锦 | Chuanxiong rhizome-containing traditional Chinese medicine composition for preventing and treating radiation |
| CN109010660A (en) * | 2018-10-25 | 2018-12-18 | 林洪生 | A kind of Chinese medicine composition and preparation method thereof improving chemotherapy patients' hematocrit level |
-
1996
- 1996-03-21 CN CN 96118646 patent/CN1160560A/en active Pending
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1092055C (en) * | 2000-06-09 | 2002-10-09 | 中国人民解放军军事医学科学院放射医学研究所 | Chinese medicine preparation |
| CN101953994A (en) * | 2010-10-11 | 2011-01-26 | 于淑萍 | Chinese medicament for treating luekopenia after concurrent chemoradiotherapy |
| CN102406757A (en) * | 2011-11-28 | 2012-04-11 | 河南科技大学第一附属医院 | Traditional Chinese medicine capsule for treating myelodysplastic syndrome and its manufacturing method |
| CN102406757B (en) * | 2011-11-28 | 2015-03-04 | 河南科技大学第一附属医院 | Traditional Chinese medicine capsule for treating myelodysplastic syndrome and its manufacturing method |
| CN102727666B (en) * | 2012-05-31 | 2014-07-30 | 固镇县中医院 | Traditional Chinese medicine for treating hepatic and renal yin deficiency type thrombocytopenia |
| CN102727666A (en) * | 2012-05-31 | 2012-10-17 | 固镇县中医院 | Traditional Chinese medicine for treating hepatic and renal yin deficiency type thrombocytopenia |
| CN103301211B (en) * | 2013-06-14 | 2015-05-13 | 袁军清 | Traditional Chinese medicine for treating leukopenia |
| CN103301211A (en) * | 2013-06-14 | 2013-09-18 | 袁军清 | Traditional Chinese medicine for treating leukopenia |
| CN103585471A (en) * | 2013-10-18 | 2014-02-19 | 张兆玺 | Traditional Chinese medicine composition for treating thrombocytopenia |
| CN103585471B (en) * | 2013-10-18 | 2015-06-10 | 张兆玺 | Traditional Chinese medicine composition for treating thrombocytopenia |
| CN103877486A (en) * | 2014-04-09 | 2014-06-25 | 刘洁 | Medicine for promoting rise of hemameba number after radiotherapy and chemotherapy and preparation method thereof |
| CN103877486B (en) * | 2014-04-09 | 2016-06-01 | 青岛市肿瘤医院 | For medicine and its preparation method of quantity of leucocyte after short lifting chemotherapy |
| CN105902970A (en) * | 2016-06-29 | 2016-08-31 | 李翠锦 | Chuanxiong rhizome-containing traditional Chinese medicine composition for preventing and treating radiation |
| CN109010660A (en) * | 2018-10-25 | 2018-12-18 | 林洪生 | A kind of Chinese medicine composition and preparation method thereof improving chemotherapy patients' hematocrit level |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1044974C (en) | Anti- hepatitis B preparation | |
| CN1062144C (en) | Yisuishengxue chinese medicine preparation for tonifying marrow and promoting generation of blood | |
| CN1184659A (en) | Traditional Chinese medicine for tonifying kidney and strengthening spleen and stomach | |
| CN102973685B (en) | Anti-fatigue traditional Chinese medicine preparation and preparation method thereof | |
| CN1562151A (en) | Medicinal formulation for treating upper respiratory track infection and its design method | |
| CN1840126A (en) | Chinese medicine for treating amblyopia and myopia | |
| CN1562160A (en) | Composite medicine for treating hepatitis B complication | |
| CN111254036A (en) | Nourishing kidney-tonifying health-preserving wine and preparation method thereof | |
| CN101062368A (en) | Chinese traditional medicine for treating cirrhosis ascites | |
| CN106333022A (en) | Compound cordyceps sinensis and ginseng instant tea and preparation method thereof | |
| CN1160560A (en) | Chinese patent drug for curing leukopenia and its preparation process | |
| CN1055837C (en) | Preparation of brain-care pill | |
| CN104621310A (en) | Health tea and application thereof | |
| CN101167932A (en) | Traditional Chinese medicine for treating chronic hepatitis B | |
| CN1063954C (en) | Chinese patent medicine-powder preparation for curing hepatitis B | |
| CN101757206A (en) | Chinese medicine preparation for treating chronic colitis | |
| CN1242775C (en) | Bushenshansong drink and preparation method thereof | |
| CN1178110A (en) | Medicine for lung cancer | |
| CN104958662A (en) | Traditional Chinese medicinal composition for treating fatty liver hepatitis and hyperlipemia and preparation method thereof | |
| CN101199667A (en) | Chinese medicine for treating leukemia, aplastic anemia | |
| CN1062176C (en) | Oral liquid for curing cancer | |
| CN104435545A (en) | Traditional Chinese medicine preparation for treating leucopenia caused by benzene poisoning | |
| CN1141780A (en) | Human-body purifying agent | |
| CN1271590A (en) | Medical capsule for curing aplastic anemia and its preparing process | |
| CN1259363A (en) | Complex prescription capsule for strengthening yang and tonifying kidney and prepn. method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |